

Vet Biotechnology Ltd (ACN 105 577 017)

NSX COMPANY ANNOUNCEMENT

NSX codes VBL, VBLO

July 25 2005 at 10:30 EST.

First Australian winner for Horse Stem Cell Therapy

Australian animal health company Vet Biotechnology announces the first racecourse success for its stem cell therapy for tendon and ligament injury.

The David Hayes trained PINIONS made a winning return to racing at Cheltenham Park on Saturday July 22.

PINIONS was treated with Vet Biotechnology's stem cell therapy by Lindsay Park Stud's Dr. Campbell Baker in September 2005 after severely injuring a tendon. The treatment involves extraction of stem cells from the horse's own bone marrow. These cells are grown in the laboratory into vastly expanded numbers then implanted into the injury site.

In July 2005 Vet Biotechnology introduced stem cell therapy into Australia, and of the horses treated PINIONS is the first Australian winner.

A number of horses have returned to the winner's stall following Stem Cell Therapy in Europe.

The recommended rehabilitation period following stem cell therapy is twelve months so further results are expected in the future.

For further information, contact:

David Bridgland	Vet Biotechnology Ltd
General Manager	ACN 105 577 017
Vet Biotechnology	Suite 7, 114 Rundle Street
Tel.: 08 8363 1159	Kent Town South Australia 5067
Mobile: 0403 777 310	Telephone: 61 8 8363 1159 Facsimile: 61 8 8362 2598
	Web page: www.vetbiotechnology.com.au